The fluoroquinolones
- PMID: 1749294
- DOI: 10.1016/s0025-6196(12)62477-x
The fluoroquinolones
Abstract
The fluoroquinolone class of antibiotics promises to become as diverse and as important as beta-lactam agents. The fluoroquinolones inhibit bacterial DNA gyrase and are bactericidal. All fluoroquinolones have potent activity against most gram-negative bacteria; ciprofloxacin is the most active against Pseudomonas aeruginosa. Activity against gram-positive organisms is variable; methicillin-resistant Staphylococcus aureus has acquired resistance to the fluoroquinolones at an alarming rate. Currently available quinolones do not have, but new quinolone agents likely will have, substantial activity against anaerobic bacteria. Some quinolones are also active against Mycobacterium, Chlamydia, and Mycoplasma organisms. All fluoroquinolones have excellent absorption after oral administration; however, this process can be impaired by the presence of aluminum- or magnesium-containing antacids and by zinc, iron, or calcium supplements. Ciprofloxacin is also available for intravenous use. Although most fluoroquinolones do not achieve adequate cerebrospinal fluid levels, penetration into other tissues is excellent. Dosage adjustments for renal and hepatic dysfunction vary among the quinolones. Although side effects are rare, concomitant use of caffeine or theophylline with some quinolones may cause toxicity to the central nervous system. Because they may affect the development of cartilage, all fluoroquinolones are contraindicated in children, adolescents, and pregnant or breast-feeding women.
Similar articles
-
[The history of the development and changes of quinolone antibacterial agents].Yakushigaku Zasshi. 2003;38(2):161-79. Yakushigaku Zasshi. 2003. PMID: 15143768 Japanese.
-
Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.Drugs. 1988 Aug;36(2):193-228. doi: 10.2165/00003495-198836020-00004. Drugs. 1988. PMID: 3053126 Review.
-
Quinolone antibacterials. An update of their pharmacology and therapeutic use.Drugs. 1994 Jun;47(6):872-901. doi: 10.2165/00003495-199447060-00003. Drugs. 1994. PMID: 7521829 Review.
-
In vitro activity of temafloxacin hydrochloride (TA-167 or A-62254), a new fluorinated 4-quinolone.Chemotherapy. 1990;36(5):345-55. doi: 10.1159/000238787. Chemotherapy. 1990. PMID: 2209168
-
In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.J Antimicrob Chemother. 1989 Mar;23(3):363-71. doi: 10.1093/jac/23.3.363. J Antimicrob Chemother. 1989. PMID: 2732120
Cited by
-
Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin.Antimicrob Agents Chemother. 1997 Jun;41(6):1298-300. doi: 10.1128/AAC.41.6.1298. Antimicrob Agents Chemother. 1997. PMID: 9174187 Free PMC article.
-
Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Canadian Ciprofloxacin Study Group.Antimicrob Agents Chemother. 1996 Jul;40(7):1729-32. doi: 10.1128/AAC.40.7.1729. Antimicrob Agents Chemother. 1996. PMID: 8807073 Free PMC article.
-
Machine learning on drug-specific data to predict small molecule teratogenicity.Reprod Toxicol. 2020 Aug;95:148-158. doi: 10.1016/j.reprotox.2020.05.004. Epub 2020 May 16. Reprod Toxicol. 2020. PMID: 32428651 Free PMC article.
-
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.Antimicrob Agents Chemother. 2000 Mar;44(3):598-601. doi: 10.1128/AAC.44.3.598-601.2000. Antimicrob Agents Chemother. 2000. PMID: 10681324 Free PMC article.
-
In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia.Antimicrob Agents Chemother. 1996 Dec;40(12):2894-7. doi: 10.1128/AAC.40.12.2894. Antimicrob Agents Chemother. 1996. PMID: 9124863 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources